KR20170018072A - 편두통을 치료 또는 경감시키는 방법 - Google Patents

편두통을 치료 또는 경감시키는 방법 Download PDF

Info

Publication number
KR20170018072A
KR20170018072A KR1020177001848A KR20177001848A KR20170018072A KR 20170018072 A KR20170018072 A KR 20170018072A KR 1020177001848 A KR1020177001848 A KR 1020177001848A KR 20177001848 A KR20177001848 A KR 20177001848A KR 20170018072 A KR20170018072 A KR 20170018072A
Authority
KR
South Korea
Prior art keywords
migraine
once
patient
compound
headache
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177001848A
Other languages
English (en)
Korean (ko)
Inventor
조셉 알. 모스칼
패트릭 스탠턴
Original Assignee
노오쓰웨스턴 유니버시티
노렉스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노오쓰웨스턴 유니버시티, 노렉스, 인크. filed Critical 노오쓰웨스턴 유니버시티
Publication of KR20170018072A publication Critical patent/KR20170018072A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177001848A 2014-06-23 2015-06-23 편두통을 치료 또는 경감시키는 방법 Ceased KR20170018072A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462015727P 2014-06-23 2014-06-23
US62/015,727 2014-06-23
US201562109386P 2015-01-29 2015-01-29
US62/109,386 2015-01-29
PCT/US2015/037177 WO2015200322A1 (en) 2014-06-23 2015-06-23 Methods of treating or ameliorating migraine

Publications (1)

Publication Number Publication Date
KR20170018072A true KR20170018072A (ko) 2017-02-15

Family

ID=54938737

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177001848A Ceased KR20170018072A (ko) 2014-06-23 2015-06-23 편두통을 치료 또는 경감시키는 방법

Country Status (10)

Country Link
EP (1) EP3157943A4 (https=)
JP (2) JP6688748B2 (https=)
KR (1) KR20170018072A (https=)
CN (1) CN106661085A (https=)
AU (1) AU2015280108B2 (https=)
BR (1) BR112016030375A8 (https=)
CA (1) CA2953170A1 (https=)
MX (1) MX2016017388A (https=)
RU (1) RU2721401C2 (https=)
WO (1) WO2015200322A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7476229B2 (ja) * 2019-04-15 2024-04-30 フェリン・ファーマシューティカルズ・インコーポレイテッド 片頭痛の治療

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006468A1 (en) * 1993-09-01 1995-03-09 Smithkline Beecham Corporation Method for treating migraine headaches
DE60131032T2 (de) * 2000-08-25 2008-08-14 Research Corp. Technologies, Inc., Tucson Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
EP1337559A2 (en) * 2000-11-17 2003-08-27 Bayer Ag Regulation of human nmda receptor
ES2381091T3 (es) * 2003-03-06 2012-05-23 Botulinum Toxin Research Associates, Inc. Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica
NZ590793A (en) * 2008-07-23 2012-07-27 Kyowa Hakko Kirin Co Ltd Therapeutic agent for migraine
WO2011003064A2 (en) * 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
PL2485751T3 (pl) * 2009-10-05 2014-10-31 Univ Northwestern GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
CN105037492A (zh) * 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
US20140107037A1 (en) * 2011-04-27 2014-04-17 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
US20150253305A1 (en) * 2012-10-12 2015-09-10 Northwestern University Methods of identifying compounds for treating depression and other related diseases

Also Published As

Publication number Publication date
BR112016030375A2 (pt) 2017-08-15
JP2017519778A (ja) 2017-07-20
CA2953170A1 (en) 2015-12-30
MX2016017388A (es) 2018-02-19
RU2017101410A3 (https=) 2019-01-21
CN106661085A (zh) 2017-05-10
AU2015280108B2 (en) 2019-11-28
BR112016030375A8 (pt) 2021-07-13
RU2017101410A (ru) 2018-07-24
WO2015200322A1 (en) 2015-12-30
JP2020114863A (ja) 2020-07-30
AU2015280108A1 (en) 2017-01-19
EP3157943A4 (en) 2018-01-24
RU2721401C2 (ru) 2020-05-19
EP3157943A1 (en) 2017-04-26
JP6688748B2 (ja) 2020-04-28

Similar Documents

Publication Publication Date Title
ES2750728T3 (es) Uso de cannabinoides en combinación con Aripriprazol
US20220160655A1 (en) Anxiolytic composition, formulation and method of use
AU2020210168B2 (en) Methods and compositions for improving cognitive function
JP2021073258A (ja) トラジピタントによる治療方法
CA2789014C (en) Methods and compositions for improving cognitive function
JP2023169413A (ja) 精神病性障害を治療するための方法および組成物
JP5030553B2 (ja) ドライマウスおよび／または唾液分泌障害を処置するための医薬
TW201605443A (zh) 治療ｘ染色體脆折症及相關病症的方法
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
US11419857B2 (en) Methods and compositions for treating pain
JP2002505306A (ja) 選択的ｎｍｄａｎｒ２ｂ拮抗薬とｃｏｘ−２阻害薬の併用
Şavk Neurologic itch management
US12042505B2 (en) Compositions and methods for treating dry eye
US20220273662A1 (en) Use of sildenafil and rock inhibitors for treating stroke or sequelae following stroke
KR20170018072A (ko) 편두통을 치료 또는 경감시키는 방법
US20240325324A1 (en) Compositions and methods for treating dry eye
Liu et al. Locus coeruleus activation contributes to masseter muscle overactivity induced by chronic restraint stress in mice
Saad et al. Nitric oxide of the supraoptic nucleus influences the salivary secretion, sodium renal excretion, urinary volume and arterial blood pressure induced by pilocarpine
Niveditha et al. Current Updates on Migrane: Diagnosis and Management
JP2024149609A (ja) 睡眠又は睡眠後パフォーマンスの改善
Goodfellow Altered NMDA Receptor Composition and Function Contribute to Deficits in Forebrain-Dependent Learning and Memory in Adult Rats Exposed to Ethanol as Neonates
TW201103546A (en) New use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170120

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200512

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211026

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220303

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211026

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I